A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals.
Looking at options history for Vertex Pharmaceuticals VRTX we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $266,785 and 3, calls, for a total amount of $162,840.
Projected Price Targets
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $420.0 to $550.0 for Vertex Pharmaceuticals during the past quarter.
Volume & Open Interest Development
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Vertex Pharmaceuticals’s options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Vertex Pharmaceuticals’s whale trades within a strike price range from $420.0 to $550.0 in the last 30 days.
Vertex Pharmaceuticals Option Activity Analysis: Last 30 Days
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VRTX | PUT | TRADE | BULLISH | 12/20/24 | $15.8 | $14.6 | $15.0 | $450.00 | $99.0K | 500 | 66 |
| VRTX | CALL | TRADE | NEUTRAL | 01/17/25 | $46.8 | $41.8 | $44.0 | $440.00 | $88.0K | 439 | 20 |
| VRTX | PUT | TRADE | BEARISH | 12/20/24 | $15.3 | $13.6 | $15.0 | $450.00 | $51.0K | 500 | 100 |
| VRTX | PUT | TRADE | BULLISH | 01/15/27 | $50.9 | $44.8 | $46.02 | $420.00 | $46.0K | 0 | 10 |
| VRTX | CALL | TRADE | BEARISH | 12/20/24 | $2.95 | $2.65 | $2.65 | $550.00 | $40.2K | 69 | 152 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Following our analysis of the options activities associated with Vertex Pharmaceuticals, we pivot to a closer look at the company’s own performance.
Vertex Pharmaceuticals’s Current Market Status
- With a volume of 565,702, the price of VRTX is up 0.06% at $466.0.
- RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.
- Next earnings are expected to be released in 77 days.
Expert Opinions on Vertex Pharmaceuticals
In the last month, 5 experts released ratings on this stock with an average target price of $492.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge’s Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.
* Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Perform rating for Vertex Pharmaceuticals, targeting a price of $486.
* Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Vertex Pharmaceuticals with a target price of $503.
* Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Vertex Pharmaceuticals, targeting a price of $540.
* An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $480.
* Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on Vertex Pharmaceuticals with a target price of $451.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Vertex Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Leave a Reply